Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial
Dr. Garon, Associate Professor of Medicine, Geffen School of Medicine at UCLA, examines dual immunotherapy approach combining atezolizumab and a drug directed against TIGIT in the CITYSCAPE trial